Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Abstract: A regimen for the therapeutic treatment of rosacea in subjects aged 65 years and older, the regimen comprising topically applying to the skin of a subject aged 65 years and older in need of said treatment a pharmaceutical composition, the pharmaceutical composition comprising about 1% w/w to about 10% w/w benzoyl peroxide as an active ingredient, and a pharmaceutically acceptable carrier or excipient, wherein the benzoyl peroxide is the only active ingredient in said pharmaceutical composition, wherein said pharmaceutical composition is applied once daily for a period of at least about 2 weeks, to achieve, in a group of such subjects, a success rate of at least about 15%, wherein the success rate is defined as the number of subjects achieving clear or almost clear skin on the investor global assessment (IGA) scale after treatment with the pharmaceutical composition.
Type:
Grant
Filed:
January 21, 2021
Date of Patent:
January 9, 2024
Assignee:
Sol-Gel Technologies Ltd.
Inventors:
Ofer Toledano, Ofra Levy-Hacham, Ori Nov, Vered Ram
Abstract: Provided herein are combination therapies for the treatment of progeroid diseases and conditions, cellular aging, bone diseases, and cardiovascular diseases. The provided combination therapies target the aberrant farnesylation of the mutant lamin A protein progerin and increase progerin clearance.
Type:
Grant
Filed:
June 30, 2020
Date of Patent:
January 2, 2024
Inventors:
Leslie B. Gordon, Mark W. Kieran, Monica E. Kleinman
Abstract: The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.
Type:
Grant
Filed:
January 25, 2021
Date of Patent:
December 19, 2023
Assignee:
Antares Pharma, Inc.
Inventors:
Paul K. Wotton, Hermanus L. Jooste, Kaushik J. Dave, Jonathan Jaffe
Abstract: The present disclosure provides, inter alia, a recombinant engineered deubiquitinase (DUB) and methods for treating or ameliorating an inherited ion channelopathy, such as long QT syndrome, Brugada syndrome, or cystic fibrosis, in a subject. Further provided are methods for screening mutations causing such inherited ion channelopathies for a trafficking-deficient mutation that is treatable by the recombinant engineered DUB disclosed herein.
Type:
Grant
Filed:
May 6, 2020
Date of Patent:
December 19, 2023
Assignee:
The Trustees of Columbia University in the City of New York
Abstract: This disclosure relates to methods of treating or preventing cystic fibrosis transmembrane conductance regulator (CFTR) mediated diseases such as cystic fibrosis, chronic obstructive pulmonary disease, chronic pancreatitis, chronic bronchitis, asthma, mucus formation, comprising administering an effective amount of a 3-(phenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide compound, salt, or derivative thereof to a subject in need thereof. In certain embodiments, the 2-amino-N?-benzylidene-acetohydrazide compound is 3-(3,5-dibromo-4-hydroxyphenyl)-N-(4-phenoxybenzyl)-1,2,4-oxadiazole-5-carboxamide.
Type:
Grant
Filed:
May 5, 2021
Date of Patent:
December 19, 2023
Assignees:
Emory University, Children's Healthcare of Atlanta, Inc.
Abstract: The present invention relates to pharmaceutical compositions and methods of manufacturing the same, comprising a eutectic of Cyclobenzaprine HCl and mannitol or Amitriptyline HCl and mannitol.
Abstract: Compounds, methods, and compositions are provided for the treatment of cancer, neurological disorders, and fibrotic disorders. Specifically, the invention includes administering an effective amount of a compound of Formula I, II, or III, or a pharmaceutically acceptable composition, salt, isotopic analog, prodrug, or combination thereof, to a subject suffering from a cancer, neurological disorder, or fibrotic disorder.
Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
Abstract: The present invention relates to pharmaceutical compositions and methods for treating ischemic stroke in humans, using a tetrafluorobenzyl derivative of formula (I) or a pharmaceutically acceptable salt thereof conjointly with a thrombolytic drug, endovascular thrombectomy, or both (e.g., endovascular thrombectomy and a thrombolytic drug). Administration of a tetrafluorobenzyl derivative of formula (I) or its pharmaceutically acceptable salt can reduce reperfusion injury and other adverse events in patients conjointly receiving a thrombolytic drug, endovascular thrombectomy, or endovascular thrombectomy with a thrombolytic drug.
Type:
Grant
Filed:
March 10, 2021
Date of Patent:
November 28, 2023
Assignee:
GNT Pharma Co., Ltd.
Inventors:
Byoung Joo Gwag, Chun San An, Jing Yu Jin, Sung Ig Cho, Fangmeng Zhu, Xinliang Xu, Weiqiang Zhan, Fuxin Liu, Soon-Mi Won
Abstract: Circulating free RNA (cfRNA) is used for monitoring status and/or treatment response for neural tumors, and especially glioma, glioblastoma, and neuroblastoma. Particularly preferred cfRNAs include those that encode a marker that is specific to a neural tumor, but also markers that are specific to DNA repair status and/or immune status.
Abstract: A composition comprising one or more polyphenols, such as oleuropein, rutin, curcumin or quercetin, can treat or prevent sarcopenia, reduce a loss of muscle functionality (e.g. muscle strength, gait speed, etc.), increase muscle functionality, and/or improve recovery of muscle functionality after muscle atrophy. The composition can be administered to an individual who is elderly and/or frail.
Type:
Grant
Filed:
August 13, 2020
Date of Patent:
November 14, 2023
Assignee:
Societe des Produits Nestle S.A.
Inventors:
Marie Noelle Horcajada, Fanny Membrez, Denis Breuille, Claire Boutry
Abstract: The present invention provides, inter alia, methods for treating or ameliorating the effects of a disorder, such as schizophrenia or bipolar disorder, by increasing or decreasing proline levels. Further provided are methods of predicting and monitoring the clinical response in a patient, and diagnostic systems for identifying a patient likely to benefit from proline modulation.
Type:
Grant
Filed:
February 28, 2020
Date of Patent:
November 14, 2023
Assignees:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK, RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.
Inventors:
Catherine L. Clelland, James D. Clelland
Abstract: Described herein are methods for distributing a combination of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone to a tissue surrounding a blood vessel for treating vascular diseases. Also disclosed are injectable compositions of a cell division inhibitor (e.g., temsirolimus or paclitaxel) and dexamethasone for delivery into the tissue surrounding a blood vessel for treating vascular diseases.
Abstract: Preparations and formulations capable of crossing and incorporating into a membrane of a cell or an organelle or an exosome are described. Methods of treatments utilizing the preparations and formulations are also described.
Abstract: Methods of reducing chemotherapy-induced metastasis, or chemotherapy-induced cancer cell dissemination, for patients subject to chemotherapy using Tie-2 inhibitors. Methods of reducing chemotherapy-induced metastasis, or chemotherapy-induced cancer cell dissemination, for patients subject to chemotherapy using inhibitors of Mena expression and/or function are also provided.
Abstract: This invention provides novel compositions comprising an anti-inflammatory agent and a mydriatic agent suitable for intraocular use, particularly ketorolac or pharmaceutically salts thereof and phenylephrine or pharmaceutically salts thereof, which are free of any buffering agent and yet, surprisingly, maintain stability for significant periods of time (e.g., at least about 3 months). The present invention also relates to a process of preparing such compositions and use thereof, e.g., in combination with intraocular ophthalmologic irrigation solutions.
Type:
Grant
Filed:
July 23, 2022
Date of Patent:
October 24, 2023
Assignee:
Somerset Therapeutics, LLC
Inventors:
Mandar V. Shah, Kumaresan Parthasarathi, Ilango Subramanian, Veerappan Subramanian, Aman Trehan
Abstract: Subject of the present invention is a diluted anesthetic solution, to be used cold, comprising the association of two different local anesthetics, one with a short duration of action and the other with a long duration of action and optionally in association with one or more adjuvant drugs having antibiotic, antifibrinolytic or antitumor action. With this association it is possible to prolong up to 150 m? duration of action in addition to offering better management of perioperative problems both as a request for analgesic drugs for post-operative pain, but also as a support to alleviate and reduce complications in some way connected to certain surgical procedures. The invention concerns also specific packaging with specific formulations, such as to make the immediate use of the mixture itself possible for different interventions.
Abstract: Presented herein are methods for treating bile acid diarrhea, short bowel syndrome (SBS), and cholecystectomy-associated diarrhea by administering to a patient in need thereof, an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. In particular embodiments, infants, and juveniles with SBS are treated with an inhibitor of chloride-ion transport in an amount sufficient to treat diarrhea. Treatment of diarrhea includes the treatment of the diarrhea as well as the pain, abdominal discomfort and other symptoms associated with diarrhea. In one embodiment, the inhibitor of chloride-ion transport is crofelemer.
Type:
Grant
Filed:
May 31, 2018
Date of Patent:
October 10, 2023
Assignee:
NAPO PHARMACEUTICALS, INC.
Inventors:
Lisa A. Conte, Pravin R. Chaturvedi, Charles Conte